S964 Culprit or Bystander? Inflammatory Bowel Disease Following Secukinumab Use in Patients With Inflammatory Arthropathy

Introduction: Secukinumab (SEC) is a human monoclonal antibody that inhibits IL-17A. It has shown significant efficacy in the treatment of psoriasis/psoriatic arthropathy (PA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS). An increased risk of developing inflammatory bowel disease (IBD) has previously been reported in patients being treated with Secukinumab. In this study, we aim to identify the association of IBD as an adverse...